SM RAFIQUL ISLAM

Research Fellow at Surgery Branch, National Cancer Institute, National Institute of Health

[Signal Transduction and Targeted Therapy (STTT) @sigtrans_sttt]

Bacteria-mimicking #Cancer cells activate multiple PRR pathways to reprogram macrophages, enhancing #Phagocytosis and antitumor immunity while improving therapeutic efficacy in #preclinicalcancer models.

#STTT #OpenAccess: https://t.co/Q3zjixPLQV

[Eric Topol @EricTopol]

An AI model trained from routine electronic health record data of 3.7 million individuals predicted cancer 1 year before clinical onset, no less promoted accuracy in detection, staging, treatment response, and prognosis
https://t.co/ORrpJ2vIcR

[Nature Rev Immunol @NatRevImmunol]

Drug holidays restore exhausted T cell responses to PD1 blockade https://t.co/WlJ9bhLayJ

[Dr. Thomas Ichim @exosome]

Finally !! a CAR-T that works on solid tumors.

Nature paper… 32 out of 36 patients had regression of advanced #cancer.

Target rglypican and tgf beta.

@IntegrativeCCA $IBRX #anktiva will enhance

https://t.co/Z9oPHIc37p

[Science Magazine @ScienceMagazine]

Researchers in Science report the development of a general-purpose biomedical AI agent that can help automate biomedical research workflows.

The authors say their results point “toward a future in which AI agents work alongside human researchers to accelerate biomedical discovery from basic research to translation.”

Learn more: https://t.co/74K6dI5iNt

[Nature Rev Immunol @NatRevImmunol]

A guide to CAR T cell therapies: development, current status and future prospects https://t.co/o4yS0Hp0b2

[Society for Immunotherapy of Cancer @sitcancer]

What’s powering the next generation of IO? Join the Panel Discussion: Next Wave IO Platforms at the 2026 SITC EU Immuno-Oncology Drug Development Summit and hear how emerging platforms are reshaping drug discovery and development. Register today: https://t.co/343COm3HUM

[Society for Immunotherapy of Cancer @sitcancer]

Immune cell engagers are transforming cancer treatment. Join Anna Farago, MD, PhD, to learn how these therapies are advancing and what they could mean for patients and drug developers. Sept. 3–4 in Lausanne, Switzerland. https://t.co/343COm3HUM

[Nature Rev Immunol @NatRevImmunol]

Programming the immunological properties of mRNA vaccines for cancer https://t.co/me4dRtNlBB

[NEJM @NEJM]

Original Article: In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia https://t.co/iAmoPdipx9

#EASCongress2026 | @EASCongress

[Marios Georgakis @MariosGeorgakis]

Human genetics has long supported the principle that the earlier, longer, and deeper we reduce LDL-C, the more atherosclerosis we can prevent.

Now, Lilly/Verve report phase 1 results of a PCSK9 gene-editing therapy offering substantial long-term LDL lowering with a single infusion.

[Vivek Subbiah, MD @VivekSubbiah]

Wow! Marked reduction of LDL cholesterol with one shot PCSK9 gene base editing 👉🏼In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia | New England Journal of Medicine @NEJM @skathire 👏🏼👏🏼👏🏼
https://t.co/IyEudrD8wV

[Eric Topol @EricTopol]

The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the most refractory cancers: pancreatic, melanoma, glioblastoma, renal, triple-negative breast cancer.
✓ out the new Ground Truths (link in profile)

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Antibody-based extracellular targeted protein degraders that destroy disease-linked proteins in cancer and autoimmunity are advancing in the clinic. Find out more in this news story in our May issue https://t.co/aOTx11x35y

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Trends in the landscape of clinical trials of innovative drugs in China since 2015
https://t.co/vbD7IbPBfa

This analysis highlights how China has become a high-volume destination for clinical trials in the past decade, driven by regulatory modernization and capital investment

[Evan Weber @EvanWeberPhD]

The manufacturing step for CAR T has always been ripe for innovation.

Here, Gattinoni and Kochenderfer groups show that pharmacologic enrichment of memory-like Tscm cells boosts CD19 CAR T expansion and durable persistence in patients, even at low doses!

https://t.co/Buxs49cJic

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The landscape for therapeutic cancer vaccines
https://t.co/EK4oljSHbx

This new article analyses the pipeline of clinical-stage therapeutic cancer vaccines, including the technology platforms, antigen selection and personalization approaches

[nature @Nature]

Nature research paper: Early fibrotic niches establish tumour-permissive microenvironments

https://t.co/59lRB5bioq

[Science Magazine @ScienceMagazine]

Immune cells continually detect, engulf, and destroy invasive microbes and cancer cells.

This process, called phagocytosis, is carried out by macrophages that must distinguish between proengulfment signals and inhibitory (“don’t-eat-me”) warnings. Cluster of differentiation 47 (CD47), a cell-surface receptor, is the archetypal don’t-eat-me signal. Many cancers upregulate CD47 expression to escape phagocytosis, and CD47 blockade promotes phagocytosis of cancer cells in mice.

However, CD47 blockers have not shown clinical benefits in patients with acute myeloid leukemia (AML), an aggressive cancer of blood immune cells. This discrepancy has raised the possibility that the molecular programs that inhibit phagocytosis differ between mice and humans.

In a new Science study, researchers report that the mechanisms that control macrophage function in human and mouse cells are indeed different. They also identify cluster of differentiation 43 (CD43) as a potential target for human AML treatment.

Learn more in a new #SciencePerspective: https://t.co/3wfJd4CFgC

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in the potential of in vivo CAR T therapies for cancer and autoimmune diseases, here's a comprehensive review
https://t.co/lBXbFGb0c2
https://t.co/VZojof75jl